Michel Goldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michel Goldman has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
Mathias Dewatripont
6 shared publications- Alain Fischer
Hôpital Necker Enfants-Malades, AP-HP Paris, Institut Imagine, Inserm U1163, Collège de France, Paris, France
3 shared publications Elie Cogan
Universite Libre de Bruxelles
3 shared publicationsAlain Fischer
2 shared publicationsMarie Neunez
2 shared publicationsPietro Ghezzi
2 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1991244
Medical AI: are Osler's principles lost in translation?
Artificial intelligence (AI) is poised to transform clinical practice, but its adoption coincides with a longstanding decline in bedside medicine. Herein, we argue that reintroducing Oslerian principles into medical training may be essential to ensure that technological progress does not come at the expense of the physician-patient relationship. Throughout, we use the term AI to refer to tools built on algorithms, from risk calculators and predictive models to large language models, that produce predictions, classifications or recommendations. These tools have no agency of their own: they operate only on the data supplied to them, and their implementation depends on how clinicians and institutions design and deploy them.William Osler never saw an algorithm. He died in 1919, a century before "artificial intelligence" entered the clinical vocabulary. And yet no figure in the history of medicine is better equipped to tell us what we are about to lose 1 . Osler's central achievement was a discipline of the mind: the conviction that the practice of medicine must rest on direct observation of the patient and on the relationship between patient and physician. We argue that this discipline is now under direct threat, and that AI tools, as currently deployed, tend to hasten its erosion rather than reverse it -unless we act deliberately to stop it. In fact, the physician-patient relationship has already been reshaped by decades of patient access to medical information through the internet and social media. This shift has been amplified by the development of health-related AI tools, which increase patients' knowledge but also expose them to misinformation and misinterpretation. Nowadays, patients often arrive at the clinical encounter having already formed their own interpretations about their disease, which directly impacts the dialogue with the physician from the very first minutes of the encounter -a dynamic Osler never had to confront. Oslerian principles must therefore be adapted to this new reality, in which both physician and patient increasingly approach the clinical encounter already shaped by algorithms.Clarifying what AI can do -and will not do in the foreseeable future AI tools can go extraordinarily far in the medical process -synthesizing literature at a scale no human can match, flagging patterns in imaging and pathology that trained eyes miss, drafting notes, triaging risk, generating differential diagnoses, and suggesting therapeutic options in seconds. None of this is in serious dispute anymore, and clinicians who dismiss it outright are being unrealistic.On the other hand, it is illusory to imagine that AI will, in the foreseeable future, replace clinical observation and the personal relationship between doctor and patient. This needs to be said plainly, not hedged. Diagnosis by patternmatching on data is not the same as sitting at the bedside of anxious patients, watching how they behave, picking up on what they leave unsaid, and actually building the trust that makes adherence possible. Whatever level of performance AI models will achieve in the future, they will remain trained on the past, and no model can substitute for what happens, uniquely, in the present, between two people.There is also a more technical reason why bedside medicine remains indispensable: AI can only reason about the reality that has been captured and digitized. An algorithm implicitly assumes that what is absent from the record does not exist. Because important information reaches the record only if a physician observes it, an algorithm working from an incomplete record can return a seemingly precise but inaccurate output, creating an illusion of certainty. Oslerian observation is therefore not a nostalgic complement to AI but a technical prerequisite for its validity: no AI tool can compensate for a hurried or incomplete examination. Far from making clinical skills obsolete, AI demands sharper skills in listening, observation and physical examination.Losing the lessons learned at the bedside is not a hypothetical risk, nor is it a new one. For decades, medical departments have been organized around organ systems and specialized technologies. This process of specialization and subspecialization -a transformation that long predates the current wave of AI adoption -has produced remarkable diagnostic and therapeutic advances, but it has also fragmented the physician's view of the patient as a whole and made a holistic approach harder to sustain. Another powerful driver of this change has been the growth of administrative and documentation burden: in ambulatory practice, a time-and-motion study found that physicians spend nearly two hours on electronic health records and desk work for every hour of direct clinical face time with patients 2 , and administrative burden has been associated with lower intrinsic motivation among physicians and poorer patient-reported experience of care 3 .Consistent with this, studies among internal medicine trainees have documented a clear decline in direct time with patients for well over a decade 4 , and the trend is still underway today in several disciplines. For example, in hematologic malignancies, where AI-based tools are being rapidly adopted to guide diagnosis, prognosis, and treatment decisions 5 , physicians increasingly spend more time in offices in front of computer screens -reviewing algorithmic outputs, multiomic profiles, and risk calculators -often making therapeutic decisions before they examine the patient, so that the consultation risks becoming a confirmation of a decision already made elsewhere, rather than the encounter from which the decision should emerge. Deployed carelessly, AI tools are likely to deepen this pattern rather than correct it. Many current incentives push in that direction: institutions will reward the efficiency of deciding early, physicians will gravitate toward the workflow that is faster and less cognitively taxing, and the tools...
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1991244
Open AccessMedical AI: are Osler's principles lost in translation?
Artificial intelligence (AI) is poised to transform clinical practice, but its adoption coincides with a longstanding decline in bedside medicine. Herein, we argue that reintroducing Oslerian principles into medical training may be essential to ensure that technological progress does not come at the expense of the physician-patient relationship. Throughout, we use the term AI to refer to tools built on algorithms, from risk calculators and predictive models to large language models, that produce predictions, classifications or recommendations. These tools have no agency of their own: they operate only on the data supplied to them, and their implementation depends on how clinicians and institutions design and deploy them.William Osler never saw an algorithm. He died in 1919, a century before "artificial intelligence" entered the clinical vocabulary. And yet no figure in the history of medicine is better equipped to tell us what we are about to lose 1 . Osler's central achievement was a discipline of the mind: the conviction that the practice of medicine must rest on direct observation of the patient and on the relationship between patient and physician. We argue that this discipline is now under direct threat, and that AI tools, as currently deployed, tend to hasten its erosion rather than reverse it -unless we act deliberately to stop it. In fact, the physician-patient relationship has already been reshaped by decades of patient access to medical information through the internet and social media. This shift has been amplified by the development of health-related AI tools, which increase patients' knowledge but also expose them to misinformation and misinterpretation. Nowadays, patients often arrive at the clinical encounter having already formed their own interpretations about their disease, which directly impacts the dialogue with the physician from the very first minutes of the encounter -a dynamic Osler never had to confront. Oslerian principles must therefore be adapted to this new reality, in which both physician and patient increasingly approach the clinical encounter already shaped by algorithms.Clarifying what AI can do -and will not do in the foreseeable future AI tools can go extraordinarily far in the medical process -synthesizing literature at a scale no human can match, flagging patterns in imaging and pathology that trained eyes miss, drafting notes, triaging risk, generating differential diagnoses, and suggesting therapeutic options in seconds. None of this is in serious dispute anymore, and clinicians who dismiss it outright are being unrealistic.On the other hand, it is illusory to imagine that AI will, in the foreseeable future, replace clinical observation and the personal relationship between doctor and patient. This needs to be said plainly, not hedged. Diagnosis by patternmatching on data is not the same as sitting at the bedside of anxious patients, watching how they behave, picking up on what they leave unsaid, and actually building the trust that makes adherence possible. Whatever level of performance AI models will achieve in the future, they will remain trained on the past, and no model can substitute for what happens, uniquely, in the present, between two people.There is also a more technical reason why bedside medicine remains indispensable: AI can only reason about the reality that has been captured and digitized. An algorithm implicitly assumes that what is absent from the record does not exist. Because important information reaches the record only if a physician observes it, an algorithm working from an incomplete record can return a seemingly precise but inaccurate output, creating an illusion of certainty. Oslerian observation is therefore not a nostalgic complement to AI but a technical prerequisite for its validity: no AI tool can compensate for a hurried or incomplete examination. Far from making clinical skills obsolete, AI demands sharper skills in listening, observation and physical examination.Losing the lessons learned at the bedside is not a hypothetical risk, nor is it a new one. For decades, medical departments have been organized around organ systems and specialized technologies. This process of specialization and subspecialization -a transformation that long predates the current wave of AI adoption -has produced remarkable diagnostic and therapeutic advances, but it has also fragmented the physician's view of the patient as a whole and made a holistic approach harder to sustain. Another powerful driver of this change has been the growth of administrative and documentation burden: in ambulatory practice, a time-and-motion study found that physicians spend nearly two hours on electronic health records and desk work for every hour of direct clinical face time with patients 2 , and administrative burden has been associated with lower intrinsic motivation among physicians and poorer patient-reported experience of care 3 .Consistent with this, studies among internal medicine trainees have documented a clear decline in direct time with patients for well over a decade 4 , and the trend is still underway today in several disciplines. For example, in hematologic malignancies, where AI-based tools are being rapidly adopted to guide diagnosis, prognosis, and treatment decisions 5 , physicians increasingly spend more time in offices in front of computer screens -reviewing algorithmic outputs, multiomic profiles, and risk calculators -often making therapeutic decisions before they examine the patient, so that the consultation risks becoming a confirmation of a decision already made elsewhere, rather than the encounter from which the decision should emerge. Deployed carelessly, AI tools are likely to deepen this pattern rather than correct it. Many current incentives push in that direction: institutions will reward the efficiency of deciding early, physicians will gravitate toward the workflow that is faster and less cognitively taxing, and the tools...
- Open Access
- 28 September 2026
- Published by Elsevier in SSRN Electronic Journal
Online health information on HPV in the French-speaking web: is Google still a vector of misinformation?
Background: Human papillomavirus (HPV) causes nearly all cervical cancers and contributes to several other cancers and health conditions. Vaccines coverage remains below the WHO 90% targets in many settings, including France and French-speaking Belgium, where hesitancy is fueled by limited health literacy, misinformation, and declining institutional trust. The quality of online content critically shapes patient knowledge and vaccination decisions.,Objective: To evaluate the quality and completeness of French-language online information on HPV and its vaccine, and assess its evolution between 2021 and 2026.,Methods: Two cross-sectional samples of 100 webpages returned by Google.be for the query "le vaccin HPV" in 2021 and 2026 were analyzed. Website typology, trustworthiness (JAMA score), and completeness across 10 prespecified domains (HPV, transmission, primary prevention, symptoms, cancer burden, secondary prevention, target population, cost, efficacy, and safety) were assessed, along with vaccine stance and misinformation debunking.,Results: Trustworthiness remained stable (median JAMA score = 3 in both years), whereas completeness improved significantly (median 8/10 vs. 5/10; p < 0.001). No webpages showed a negative vaccine stance in either sample. Pro-vaccine content increased from 78% to 98% (p = 0.0001). Misinformation debunking rose from 22% to 35% (p = 0.06). Governmental websites scored highest for completeness, while transmission, primary prevention, and cancer burden were the least addressed topics.,Conclusion: French-language HPV information became more complete and more consistently pro-vaccine between 2021 and 2026, while trustworthiness remained stable. Persisting gaps in specific domains support the need for targeted improvement of publicly available HPV information.
- 28 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessOnline health information on HPV in the French-speaking web: is Google still a vector of misinformation?
Background: Human papillomavirus (HPV) causes nearly all cervical cancers and contributes to several other cancers and health conditions. Vaccines coverage remains below the WHO 90% targets in many settings, including France and French-speaking Belgium, where hesitancy is fueled by limited health literacy, misinformation, and declining institutional trust. The quality of online content critically shapes patient knowledge and vaccination decisions.,Objective: To evaluate the quality and completeness of French-language online information on HPV and its vaccine, and assess its evolution between 2021 and 2026.,Methods: Two cross-sectional samples of 100 webpages returned by Google.be for the query "le vaccin HPV" in 2021 and 2026 were analyzed. Website typology, trustworthiness (JAMA score), and completeness across 10 prespecified domains (HPV, transmission, primary prevention, symptoms, cancer burden, secondary prevention, target population, cost, efficacy, and safety) were assessed, along with vaccine stance and misinformation debunking.,Results: Trustworthiness remained stable (median JAMA score = 3 in both years), whereas completeness improved significantly (median 8/10 vs. 5/10; p < 0.001). No webpages showed a negative vaccine stance in either sample. Pro-vaccine content increased from 78% to 98% (p = 0.0001). Misinformation debunking rose from 22% to 35% (p = 0.06). Governmental websites scored highest for completeness, while transmission, primary prevention, and cancer burden were the least addressed topics.,Conclusion: French-language HPV information became more complete and more consistently pro-vaccine between 2021 and 2026, while trustworthiness remained stable. Persisting gaps in specific domains support the need for targeted improvement of publicly available HPV information.
- Open Access
- 30 July 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 68
Rebalancing innovation, affordability, and access for orphan drugs in the European Union
- 30 July 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 68
Open AccessRebalancing innovation, affordability, and access for orphan drugs in the European Union
- Open Access
- 18 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12
Editorial: Pioneers & pathfinders: 10 years of frontiers in medicine
- 18 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12
Open AccessEditorial: Pioneers & pathfinders: 10 years of frontiers in medicine
- Open Access
- 16 December 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (2) , 666-719
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence of several variants during the pandemic has presented numerous challenges in preventing and managing this disease. The development of vaccines has played a pivotal role in controlling the pandemic, with a significant portion of the global population being vaccinated. This, along with the emergence of less virulent SARS-CoV-2 variants, has led to a reduction in the severity of COVID-19 outcomes for the overall population. Nevertheless, individuals with immunocompromising conditions continue to face challenges given their suboptimal response to vaccination and vulnerability to severe COVID-19. This expert review synthesizes recent published evidence regarding the economic and human impact of COVID-19 on such individuals. The literature suggests that rates of hospitalization, intensive care unit admission, and mechanical ventilation use were high during the pre-Omicron era, and remained high during Omicron and later, despite vaccination for this population. Moreover, studies indicated that these individuals experienced a negative impact on their mental health and health-related quality of life (HRQoL) compared to those without immunocompromising conditions, with elevated levels of anxiety, depression, and distress reported. Further, these individuals with immunocompromising conditions experienced substantial costs associated with COVID-19 and loss of income during the pandemic, though the evidence on the economic burden of COVID-19 in such individuals is limited. Generally, COVID-19 has increased healthcare resource use and costs, impaired mental health, and reduced HRQoL in those with varied immunocompromising conditions compared to both those without COVID-19 and the general population—underscoring the importance of continued real-world studies. Ongoing research is crucial to assess the ongoing burden of COVID-19 in vaccinated individuals with immunocompromising conditions who are still at risk of severe COVID-19 outcomes to ensure their needs are not disproportionately worse than the general population.
- 16 December 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (2) , 666-719
Open AccessIs COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence of several variants during the pandemic has presented numerous challenges in preventing and managing this disease. The development of vaccines has played a pivotal role in controlling the pandemic, with a significant portion of the global population being vaccinated. This, along with the emergence of less virulent SARS-CoV-2 variants, has led to a reduction in the severity of COVID-19 outcomes for the overall population. Nevertheless, individuals with immunocompromising conditions continue to face challenges given their suboptimal response to vaccination and vulnerability to severe COVID-19. This expert review synthesizes recent published evidence regarding the economic and human impact of COVID-19 on such individuals. The literature suggests that rates of hospitalization, intensive care unit admission, and mechanical ventilation use were high during the pre-Omicron era, and remained high during Omicron and later, despite vaccination for this population. Moreover, studies indicated that these individuals experienced a negative impact on their mental health and health-related quality of life (HRQoL) compared to those without immunocompromising conditions, with elevated levels of anxiety, depression, and distress reported. Further, these individuals with immunocompromising conditions experienced substantial costs associated with COVID-19 and loss of income during the pandemic, though the evidence on the economic burden of COVID-19 in such individuals is limited. Generally, COVID-19 has increased healthcare resource use and costs, impaired mental health, and reduced HRQoL in those with varied immunocompromising conditions compared to both those without COVID-19 and the general population—underscoring the importance of continued real-world studies. Ongoing research is crucial to assess the ongoing burden of COVID-19 in vaccinated individuals with immunocompromising conditions who are still at risk of severe COVID-19 outcomes to ensure their needs are not disproportionately worse than the general population.
- 1 August 2024
- Published by University of Chicago Press in Journal of Political Economy
- Vol. 132 (8) , 2655-2694
The Morality of Markets
- 1 August 2024
- Published by University of Chicago Press in Journal of Political Economy
- Vol. 132 (8) , 2655-2694
The Morality of Markets
- Open Access
- 23 May 2024
- Published by Frontiers Media SA in Frontiers in Science
- Vol. 2, 1236919
Standing the test of COVID-19: charting the new frontiers of medicine
The COVID-19 pandemic accelerated research and innovation across numerous fields of medicine. It emphasized how disease concepts must reflect dynamic and heterogeneous interrelationships between physical characteristics, genetics, co-morbidities, environmental exposures, and socioeconomic determinants of health throughout life. This article explores how scientists and other stakeholders must collaborate in novel, interdisciplinary ways at these new frontiers of medicine, focusing on communicable diseases, precision/personalized medicine, systems medicine, and data science. The pandemic highlighted the critical protective role of vaccines against current and emerging threats. Radical efficiency gains in vaccine development (through mRNA technologies, public and private investment, and regulatory measures) must be leveraged in the future together with continued innovation in the area of monoclonal antibodies, novel antimicrobials, and multisectoral, international action against communicable diseases. Inter-individual heterogeneity in the pathophysiology of COVID-19 prompted the development of targeted therapeutics. Beyond COVID-19, medicine will become increasingly personalized via advanced omics-based technologies and systems biology—for example targeting the role of the gut microbiome and specific mechanisms underlying immunoinflammatory diseases and genetic conditions. Modeling proved critical to strengthening risk assessment and supporting COVID-19 decision-making. Advanced computational analytics and artificial intelligence (AI) may help integrate epidemic modeling, clinical features, genomics, immune factors, microbiome data, and other anthropometric measures into a “systems medicine” approach. The pandemic also accelerated digital medicine, giving telehealth and digital therapeutics critical roles in health system resilience and patient care. New research methods employed during COVID-19, including decentralized trials, could benefit evidence generation and decision-making more widely. In conclusion, the future of medicine will be shaped by interdisciplinary multistakeholder collaborations that address complex molecular, clinical, and social interrelationships, fostering precision medicine while improving public health. Open science, innovative partnerships, and patient-centricity will be key to success.
- 23 May 2024
- Published by Frontiers Media SA in Frontiers in Science
- Vol. 2, 1236919
Open AccessStanding the test of COVID-19: charting the new frontiers of medicine
The COVID-19 pandemic accelerated research and innovation across numerous fields of medicine. It emphasized how disease concepts must reflect dynamic and heterogeneous interrelationships between physical characteristics, genetics, co-morbidities, environmental exposures, and socioeconomic determinants of health throughout life. This article explores how scientists and other stakeholders must collaborate in novel, interdisciplinary ways at these new frontiers of medicine, focusing on communicable diseases, precision/personalized medicine, systems medicine, and data science. The pandemic highlighted the critical protective role of vaccines against current and emerging threats. Radical efficiency gains in vaccine development (through mRNA technologies, public and private investment, and regulatory measures) must be leveraged in the future together with continued innovation in the area of monoclonal antibodies, novel antimicrobials, and multisectoral, international action against communicable diseases. Inter-individual heterogeneity in the pathophysiology of COVID-19 prompted the development of targeted therapeutics. Beyond COVID-19, medicine will become increasingly personalized via advanced omics-based technologies and systems biology—for example targeting the role of the gut microbiome and specific mechanisms underlying immunoinflammatory diseases and genetic conditions. Modeling proved critical to strengthening risk assessment and supporting COVID-19 decision-making. Advanced computational analytics and artificial intelligence (AI) may help integrate epidemic modeling, clinical features, genomics, immune factors, microbiome data, and other anthropometric measures into a “systems medicine” approach. The pandemic also accelerated digital medicine, giving telehealth and digital therapeutics critical roles in health system resilience and patient care. New research methods employed during COVID-19, including decentralized trials, could benefit evidence generation and decision-making more widely. In conclusion, the future of medicine will be shaped by interdisciplinary multistakeholder collaborations that address complex molecular, clinical, and social interrelationships, fostering precision medicine while improving public health. Open science, innovative partnerships, and patient-centricity will be key to success.
- Open Access
- 23 May 2024
- Published by Frontiers Media SA in Frontiers for Young Minds
- Vol. 12
Toward a Healthier Future: Lessons From the COVID-19 Pandemic
The COVID-19 pandemic was a challenging time—many people got sick and even died, most people had to stay home from school and work, and fun things like going to the movies, traveling, and visiting friends and family were discouraged. However, the pandemic also taught us some key lessons. We learned that it is important for scientists and doctors to work together closely to understand health threats. Collaboration led to fast production of a safe, effective, COVID-19 vaccine. We learned that diseases can quickly spread all over the world, which taught us about the need for global cooperation and equal access to vaccination and other health services. The pandemic also showed us how critical it is to understand health information, so that we can tell accurate information apart from false claims. These lessons will shape our future, hopefully leading to even greater advances in science and healthcare that will create a healthier world.
- 23 May 2024
- Published by Frontiers Media SA in Frontiers for Young Minds
- Vol. 12
Open AccessToward a Healthier Future: Lessons From the COVID-19 Pandemic
The COVID-19 pandemic was a challenging time—many people got sick and even died, most people had to stay home from school and work, and fun things like going to the movies, traveling, and visiting friends and family were discouraged. However, the pandemic also taught us some key lessons. We learned that it is important for scientists and doctors to work together closely to understand health threats. Collaboration led to fast production of a safe, effective, COVID-19 vaccine. We learned that diseases can quickly spread all over the world, which taught us about the need for global cooperation and equal access to vaccination and other health services. The pandemic also showed us how critical it is to understand health information, so that we can tell accurate information apart from false claims. These lessons will shape our future, hopefully leading to even greater advances in science and healthcare that will create a healthier world.
- 14 March 2024
- Published by Elsevier in The Lancet
- Vol. 403 (10431) , 1023
Inflammation, infection, and cardiovascular risk
- 14 March 2024
- Published by Elsevier in The Lancet
- Vol. 403 (10431) , 1023
Inflammation, infection, and cardiovascular risk
- Open Access
- 9 January 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1348376
Case reports as early safety signals: learning from the COVID-19 vaccination campaign
Case reports as early safety signals: learning from the COVID-19 vaccination campaign
- 9 January 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1348376
Open AccessCase reports as early safety signals: learning from the COVID-19 vaccination campaign
Case reports as early safety signals: learning from the COVID-19 vaccination campaign